Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy with Checkpoint Inhibitors Across Cancer Diagnoses
NCT03296137Phase 2Completed
- Start
- Oct 2017
- Primary completion
- Mar 2020
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in solid tumor. Primary endpoint: Number of Participants and Type of Reported Adverse Events up to 2.5 years. Started Oct 2017; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03296137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296137.